The genetics of drug efficacy: opportunities and challenges

@article{Nelson2016TheGO,
  title={The genetics of drug efficacy: opportunities and challenges},
  author={Matthew R. Nelson and Toby Johnson and Liling Warren and Arlene R. Hughes and Stephanie L. Chissoe and Chun-Fang Xu and Dawn Waterworth},
  journal={Nature Reviews Genetics},
  year={2016},
  volume={17},
  pages={197-206}
}
Lack of sufficient efficacy is the most common cause of attrition in late-phase drug development. It has long been envisioned that genetics could drive stratified drug development by identifying those patient subgroups that are most likely to respond. However, this vision has not been realized as only a small proportion of drugs have been found to have germline genetic predictors of efficacy with clinically meaningful effects, and so far all but one were found after drug approval. With the… CONTINUE READING

Figures, Tables, and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

A scientist engineer's contribution to therapeutic discovery and development.

  • Experimental biology and medicine
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 84 REFERENCES

Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib

Spraggs, F C.
  • Ann. Oncol
  • 2015

The support of human genetic evidence for approved drug indications

Nelson, R M.
  • Nat. Genet
  • 2015

experiment and/or computation? Nat

Kirchmair, J. et al. Predicting drug metabolism
  • Rev. Drug Discov. 14, 387–404
  • 2015

Characterization of statin dose response in electronic medical records

Wei, Q W.
  • Clin. Pharmacol. Ther
  • 2014